<DOC>
	<DOCNO>NCT00031590</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining low-dose radiation therapy combination chemotherapy may effective treat primitive neuroectodermal tumor medulloblastoma . PURPOSE : This phase II trial study give low-dose radiation therapy together combination chemotherapy surgery see well work treat child newly diagnose primitive neuroectodermal tumor medulloblastoma .</brief_summary>
	<brief_title>Low-Dose Radiation Therapy Combination Chemotherapy Following Surgery Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor Medulloblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Reduce late cognitive , auditory , endocrinologic effect child newly diagnose standard-risk posterior fossa primitive neuroectodermal tumor medulloblastoma reduce adjuvant craniospinal radiotherapy dose 25 % , maintain therapeutic efficacy ( 86 % 3-year relapse-free survival ) current standard therapy use maintenance chemotherapy comprise lomustine , cisplatin , vincristine alternate cyclophosphamide etoposide . - Evaluate acute subacute toxicity regimen patient . - Evaluate late neurotoxic effect low-dose craniospinal radiotherapy , term cognitive , endocrinologic , auditory function , patient . OUTLINE : This multicenter study . - Adjuvant induction chemoradiotherapy : Beginning within 28 day prior resection , patient undergo radiotherapy craniospinal axis 5 day week 2 week conformal radiotherapy tumor bed 5 day week 4 week . Beginning 1 week initiation radiotherapy , patient receive vincristine IV weekly 6 week . - Maintenance chemotherapy : Beginning 4 week completion induction chemoradiotherapy , patient receive two 6-week course regimen A outline alternated one 6-week course regimen B outline total 9 course ( 6 course regimen A 3 course regimen B ) . - Regimen A : Patients receive oral lomustine cisplatin IV 8 hour day 0 vincristine IV day 0 , 7 , 14 . - Regimen B : Patients receive cyclophosphamide IV day 0 1 etoposide IV day 0 1 orally day 14-34 . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Histologically confirm posterior fossa primitive neuroectodermal tumor medulloblastoma 2 . Standardrisk disease 3 . No residual tumor great 1.5 cm^2 resection postoperative MRI No tumor spinal cerebral subarachnoid space MRI No tumor subarachnoid space Cerebrospinal fluid ( CSF ) No failure perform stag study ( spine MRI CSF cytology ) preoperatively postoperatively 4 . Must begin radiotherapy study within 28 day surgery 1 . Prior radiotherapy antitumor chemotherapy corticosteroid allow . 2 . Pregnant female eligible 3 . Patients must begin radiotherapy protocol within 28 day completion surgery . Exceptions need approve Principal Investigator . 4 . Patients follow eligible : &gt; 1.5cm3 residual tumor follow resection indicate postoperative MRI . tumor spinal cerebral subarachnoid space either MRI brain spine tumor subarachnoid space CSF cytology failure perform stag study ( spine MRI , CSF cytology ) either pre post operatively</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>PNET</keyword>
	<keyword>craniospinal radiotherapy</keyword>
</DOC>